JP2009525478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525478A5 JP2009525478A5 JP2008552858A JP2008552858A JP2009525478A5 JP 2009525478 A5 JP2009525478 A5 JP 2009525478A5 JP 2008552858 A JP2008552858 A JP 2008552858A JP 2008552858 A JP2008552858 A JP 2008552858A JP 2009525478 A5 JP2009525478 A5 JP 2009525478A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- prongf
- body fluid
- biological sample
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600851 | 2006-01-31 | ||
| FR0600851A FR2896881B1 (fr) | 2006-01-31 | 2006-01-31 | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| PCT/FR2007/050708 WO2007088305A1 (fr) | 2006-01-31 | 2007-01-30 | Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012124525A Division JP5792121B2 (ja) | 2006-01-31 | 2012-05-31 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525478A JP2009525478A (ja) | 2009-07-09 |
| JP2009525478A5 true JP2009525478A5 (enExample) | 2010-03-04 |
| JP5091876B2 JP5091876B2 (ja) | 2012-12-05 |
Family
ID=36741378
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552858A Active JP5091876B2 (ja) | 2006-01-31 | 2007-01-30 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
| JP2012124525A Active JP5792121B2 (ja) | 2006-01-31 | 2012-05-31 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012124525A Active JP5792121B2 (ja) | 2006-01-31 | 2012-05-31 | 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8008009B2 (enExample) |
| EP (1) | EP1982192B1 (enExample) |
| JP (2) | JP5091876B2 (enExample) |
| CN (2) | CN103446585A (enExample) |
| ES (1) | ES2471126T3 (enExample) |
| FR (1) | FR2896881B1 (enExample) |
| WO (1) | WO2007088305A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| FR2944019B1 (fr) * | 2009-04-03 | 2011-04-22 | Biomerieux Sa | Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal. |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| CN101782585A (zh) * | 2010-02-10 | 2010-07-21 | 广州医学院 | 肺癌组织蛋白印迹膜片及其制备方法 |
| US20130115222A1 (en) * | 2010-06-15 | 2013-05-09 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| US20140295426A1 (en) * | 2011-07-28 | 2014-10-02 | Veridex Llc | Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids |
| WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| ES2945036T3 (es) | 2012-08-16 | 2023-06-28 | Veracyte Sd Inc | Pronóstico del cáncer de próstata mediante biomarcadores |
| CN103122390B (zh) * | 2013-03-07 | 2015-04-08 | 上海市疾病预防控制中心 | Frat1基因作为检测甲状腺癌的血清标志物及其应用 |
| EP2968988A4 (en) | 2013-03-14 | 2016-11-16 | Allegro Diagnostics Corp | METHOD FOR EVALUATING A COPD STATUS |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| CN103866039B (zh) * | 2014-04-04 | 2015-05-27 | 厦门大学 | 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用 |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP2977759B1 (en) * | 2014-07-25 | 2017-07-12 | Serum Institute of India Private Limited | Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
| HUE057432T2 (hu) | 2015-04-07 | 2022-05-28 | Alector Llc | Anti-sortilin antitestek és ezek alkalmazási módjai |
| AU2017315425B2 (en) | 2016-08-24 | 2023-11-09 | The Regents Of The University Of Michigan | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| EP3571322B9 (en) | 2017-01-20 | 2023-10-04 | VERACYTE SD, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| WO2018136995A1 (en) * | 2017-01-24 | 2018-08-02 | Genetic Technologies Limited | Improved methods for assessing risk of developing breast cancer |
| CA3055925A1 (en) | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
| WO2018224761A1 (fr) * | 2017-06-08 | 2018-12-13 | Carcidiag Biotechnologies | Methode d'isolement et de detection de cellules souches cancereuses |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| US12497660B2 (en) | 2017-08-04 | 2025-12-16 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| RS64034B1 (sr) | 2018-07-13 | 2023-04-28 | Alector Llc | Anti-sortilin antitela i načini njihove upotrebe |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| US20050079557A1 (en) | 2002-03-13 | 2005-04-14 | Bio Merieux | Method for the detection and/or characterisation of circulating tumour cells and the use thereof in the early diagnosis, prognosis and diagnosis of relapses and in the selection and evaluation of therapeutic treatments |
| FR2846426B1 (fr) | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| DK1891966T3 (da) * | 2002-12-20 | 2012-04-02 | Lundbeck & Co As H | Modulation af neurotrophinaktivitet; fremgangsmåde til screening |
| US20050282840A1 (en) * | 2004-02-11 | 2005-12-22 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
-
2006
- 2006-01-31 FR FR0600851A patent/FR2896881B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-30 EP EP07731536.4A patent/EP1982192B1/fr active Active
- 2007-01-30 JP JP2008552858A patent/JP5091876B2/ja active Active
- 2007-01-30 US US12/087,606 patent/US8008009B2/en active Active
- 2007-01-30 WO PCT/FR2007/050708 patent/WO2007088305A1/fr not_active Ceased
- 2007-01-30 ES ES07731536.4T patent/ES2471126T3/es active Active
- 2007-01-30 CN CN2013103889291A patent/CN103446585A/zh active Pending
- 2007-01-30 CN CN2007800040238A patent/CN101395478B/zh not_active Expired - Fee Related
-
2011
- 2011-07-20 US US13/137,101 patent/US20110293636A1/en not_active Abandoned
-
2012
- 2012-05-31 JP JP2012124525A patent/JP5792121B2/ja active Active
- 2012-06-26 US US13/533,908 patent/US9061045B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525478A5 (enExample) | ||
| Wilmott et al. | Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | |
| Houshmand et al. | Chronic myeloid leukemia stem cells | |
| Liu et al. | Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis | |
| Mercer et al. | Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF | |
| Jimeno et al. | A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development | |
| Savas et al. | Clinical relevance of host immunity in breast cancer: from TILs to the clinic | |
| Wu et al. | Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo | |
| US9670550B2 (en) | Method for examination of carcinogenic risk | |
| Huang et al. | Cartilage decellularized matrix hydrogel loaded with protocatechualdehyde for targeted epiphycan treatment of osteoarthritis | |
| US12352752B2 (en) | Application of Niemann-Pick C1 protein in diagnosis and treatment of cancer | |
| Chu et al. | Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non–small-cell lung cancer receiving endostatin and paclitaxel–carboplatin chemotherapy? A Retrospective Study | |
| Wang et al. | The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography | |
| Dudek et al. | Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma | |
| Lerévérend et al. | Enhanced expression of galectin‐9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy | |
| Tarhini et al. | Operable melanoma: screening, prognostication, and adjuvant and neoadjuvant therapy | |
| US20090226901A1 (en) | Method of evaluating or selecting agents for preventing or improving pigmented spots | |
| CN112262157A (zh) | 化药抗性癌症的组合治疗 | |
| Dai et al. | Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity | |
| US20210208161A1 (en) | CCL24 as a Diagnostic and Therapeutic Target for Breast Cancer | |
| Ollila-Raj et al. | Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing | |
| RU2436102C1 (ru) | Способ прогнозирования метастазов рака шейки матки | |
| WO2013029202A1 (zh) | 谷草转氨酶和乳酸脱氢酶的检测在早期评估抗肿瘤干预措施临床疗效中的应用 | |
| Robertson | THE PLANTAR MECHANICAL MICROENVIRONMENT PROMOTES PROLIFERATION AND INVASION OF ACRAL MELANOMAS | |
| He et al. | The Expression of PD-L1, CD47, CD4, and CD8 in Breast Cancer before and after Neoadjuvant Chemotherapy and Their Relationship with Clinicopathological Features and Prognosis |